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Aims Sirtuin 3 (Sirt3) is a mitochondrial, nicotinamide adenine dinucleotide (NADþ)-dependent deacetylase that reduces
oxidative stress by activation of superoxide dismutase 2 (SOD2). Oxidative stress enhances arterial thrombosis.
This study investigated the effects of genetic Sirt3 deletion on arterial thrombosis in mice in an inflammatory setting
and assessed the clinical relevance of these findings in patients with ST-elevation myocardial infarction (STEMI).
....................................................................................................................................................................................................
Methods
and results
Using a laser-induced carotid thrombosis model with lipopolysaccharide (LPS) challenge, in vivo time to thrombotic
occlusion in Sirt3-/- mice (n= 6) was reduced by half compared to Sirt3þ/þ wild-type (n= 8, P< 0.01) controls.
Ex vivo analyses of whole blood using rotational thromboelastometry revealed accelerated clot formation and
increased clot stability in Sirt3-/- compared to wild-type blood. rotational thromboelastometry of cell-depleted
plasma showed accelerated clotting initiation in Sirt3-/- mice, whereas overall clot formation and firmness remained
unaffected. Ex vivo LPS-induced neutrophil extracellular trap formation was increased in Sirt3-/- bone marrow-
derived neutrophils. Plasma tissue factor (TF) levels and activity were elevated in Sirt3-/- mice, whereas plasma levels
of other coagulation factors and TF expression in arterial walls remained unchanged. SOD2 expression in bone
marrow -derived Sirt3-/- neutrophils was reduced. In STEMI patients, transcriptional levels of Sirt3 and its target
SOD2 were lower in CD14þ leukocytes compared with healthy donors (n= 10 each, P< 0.01).
....................................................................................................................................................................................................
Conclusions Sirt3 loss-of-function enhances experimental thrombosis in vivo via an increase of neutrophil extracellular traps and
elevation of TF suggesting thrombo-protective effects of endogenous Sirt3. Acute coronary thrombosis in STEMI
patients is associated with lower expression levels of SIRT3 and SOD2 in CD14þ leukocytes. Therefore, enhancing
SIRT3 activity by pan-sirtuin activating NADþ-boosters may provide a novel therapeutic target to prevent or treat
thrombotic arterial occlusion in myocardial infarction or stroke.
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1. Introduction
Myocardial infarction is caused by acute thrombotic occlusion of an epi-
cardial coronary artery and accounts for almost 20% of deaths in Europe
in 2015.1 A major trigger of arterial thrombosis is endothelial activation
or dysfunction, which activates tissue factor (TF), a key initiator of the
coagulation cascade. In the context of an acute myocardial infarction, the
formation of coagulation factors is enhanced by inflammatory stimuli and
reactive oxygen species (ROS) thereby accelerating thrombus formation
by increasing platelet activation and aggregation and by inhibiting fibrinol-
ysis.2 Furthermore, activated endothelial cells express adhesion mole-
cules that recruit platelets, monocytes, and neutrophils. Interestingly,
neutrophils are among the first cells to reach sites of endothelial activa-
tion and damage, where they bind to expressed adhesion molecules or
exposed subendothelial layers stimulate the expression of TF and
thereby initiate coagulation. In line with this concept, inhibiting neutro-
phil adhesion is associated with reduced amounts of TF.3
Neutrophils exhibit several lines of defence for pathogen elimination
in the blood stream, i.e. degranulation, phagocytosis, and formation of
neutrophil extracellular traps (NETs), an event where ROS play a key
role.4 NET formation has been considered a programmed cell death
mechanism (Enosis), whereby the intracellular content of neutrophils is
externalized in a web-like structure that is able to kill microbes.5 This
view has recently been challenged by observations that NETs mainly
consist of mitochondrial DNA and that neutrophils remain viable after
releasing NETs. A trigger of NET formation is bacterial endotoxemia,
which is derived from the gut microbiome and induces a pro-
inflammatory state that is associated with cardiovascular disease (CVD)
in humans.6 One of the endotoxins that accelerate CVD is lipopolysac-
charide (LPS), a component of the bacterial cell membrane. In neutro-
phils, LPS induces ROS production and enhances NET formation.5,7
NETs display strong prothrombotic properties as they bind several pro-
teins such as TF that initiate coagulation and promote thrombin genera-
tion.8,9 Indeed, NETs have been associated with the severity of
atherosclerosis and thrombosis and have been identified in human coro-
nary thrombi, at lesion sites of ST-elevation myocardial infarction
(STEMI).10
Sirtuins comprise a family of seven highly conserved nicotinamide
adenine dinucleotide (NADþ)-dependent deacetylases and ribosylases
with protective effects in aging, apoptosis, inflammation, and oxidative
stress.11,12 Evidence for a putative role of sirtuins in thrombosis is limited
to a study of pharmacological inhibition of the nuclear sirtuin 1 (Sirt1),
which augments arterial thrombosis by increasing TF expression and
activity through activation of NFjB,13 and an associative study suggesting
that inhibition of sirtuin 1, 2 or 3 worsens thrombosis by inducing
apoptosis-like changes in platelets.14
Mitochondrial sirtuin 3 (Sirt3) maintains mitochondrial function in
low-energy conditions and activates anti-oxidant defence mechanisms.15
Sirt3 deacetylases and thus, activates superoxide dismutase 2 (Sod2), the
main scavenger of superoxide radicals in mitochondria.16 Sirt3 also upre-
gulates expression of Sod2 and catalase, another ROS scavenger in the
mitochondria.17 Along these lines, a protective role of Sirt3 has been
implicated in metabolic, age-, and oxidative stress-related diseases.18
Interestingly, Sirt3-/- mice exhibit mitochondrial protein hyperacetylation,
but remain metabolically normal under basal conditions. Indeed, histo-
logical examinations of liver, brown adipose tissue, heart, brain, kidney,
and skeletal muscle, mitochondrial numbers, body weight, and fat con-
tent, as well as energy balance were not different when comparing Sirt3-/-
mice to their wild-type (WT) littermates.19 However, loss of Sirt3 in
combination with a high-cholesterol diet is sufficient to disturb this equi-
librium: Under these conditions, the metabolic derangement increases
oxidative stress in endothelial mitochondria and induces mild endothelial
dysfunction.20 Notably, the role of Sirt3 in arterial thrombosis remains
unknown. Thus, we hypothesized that constitutive Sirt3 loss-of-function
increases oxidative stress in vascular cells, increases procoagulant prop-
erties and eventually accelerates arterial thrombus formation.
2. Methods
Primer sequences are available in the supplementary material at
Cardiovascular Research online.
2.1 Mice
Mice with a germline Sirt3 deletion were obtained and congenic
C57BL6/J Sirt3-/- mice were generated through nine generations of back-
crosses with C57BL6/J mice.21,22 Sirt3þ/þ WT and Sirt3-/- mice were kept
in a temperature-controlled facility with a 12-h light/dark cycle and free
access to normal chow and water for 16 weeks. All animal experiments
were approved by, and carried out in accordance with local veterinary
authorities (Veterinary Office of the Canton Zurich, permit numbers:
239/2013 and ZH023/17), as well as the guidelines from Directive 2010/
63/EU and institutional guidelines. Mice were administered an intraperi-
toneal injection of 5 mg/kg LPS (E. coli O111: B4, Sigma–Aldrich) 10 h
prior to experiments or organ harvesting, respectively.
2.2 Laser-induced carotid thrombosis
in vivo
Carotid thrombosis was performed using male WT and Sirt3-/- mice.
Mice were anaesthetized using 87 mg/kg sodium pentobarbital (Butler).
Rose bengal (Fisher Scientific) was injected in the tail vein at a concentra-
tion of 63 mg/kg. The right common carotid artery was exposed follow-
ing a midline cervical incision. A Doppler flow probe (Transonic
Systems) was applied and connected to a flowmeter (Transonic, Model
T106) and a 1.5mW green laser (540 nm; Melles Griot) was applied to
the site of injury at a distance of 6 cm for 60 min. Blood flow was moni-
tored from laser onset for maximum 120 min, or until occlusion
(flow <_0.1 mL for 1 min) occurred.
2.3 NET formation
Neutrophils were isolated from mouse bone marrows (BM) using gra-
dient centrifugation.23 For each condition, 50 000 cells were plated into
one well of a black, clear-bottom 96 well plate (Corning) and incubated
for 30 min at 37C. All wells were then supplied with 5mM SYTOX
Green (ThermoFisher Scientific) and, thereafter, stimulated with
2mg/mL LPS (E. coli O111: B4, Sigma–Aldrich) or vehicle control.
Fluorescence (ex/em = 488/523) was measured every 5 min over 4 h at
37C in a plate reader (Tecan).
2.4 Human samples
Patients with acute coronary syndromes (ACS) were prospectively
enrolled between 2009 and 2012 into the multicentre Swiss SPUM-ACS
cohort (NCT01000701). Inclusion criteria for this subgroup of patients
recruited at the University Hospital Zurich comprised diagnosis of
STEMI, age >_18 years and presentation within 72 h after pain onset.
Exclusion criteria were severe physical disability, inability to comprehend
study or life expectancy <1 year for non-cardiac reasons.
2 D.S. Gaul et al.
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Healthy individuals were recruited from the local blood bank and
invited for an outpatient visit at University Hospital Zurich. Individuals
were eligible if none of the following exclusion criteria were found by
history, clinical exam, blood analysis or echocardiogram: Age <18 years,
use of cardiovascular medication, positive cardiovascular family history,
smoking (including cessation of smoking within 2 years prior to study
enrolment), history of hypertension, elevated total cholesterol
(>_5.0 mmol/L), BMI > 30 kg/m2, history of diabetes mellitus, evidence of
relevant valvular or structural heart disease and/or a reduced LV ejection
fraction (LVEF; <55%) on echocardiogram.
In STEMI patients, blood was drawn at the beginning of catheterization
(after sheath insertion). Leukocytes were separated from whole blood
by Ficoll density gradient centrifugation (400 RCF, 30 min at 22C).
Cells were stained for 10 min on ice using human CD14-FITC antibody
(Miltenyi Biotec) and subsequently sorted using a FACSAria III 4 L (BD
Biosciences). RNA of CD14þ cells was isolated and analysed as
described in the Supplemental material online.
The study complies with the Declaration of Helsinki, and the locally
appointed ethics committee approved the research protocol. Informed
consent was obtained from all subjects.
2.5 Rotational thromboelastometry
Whole blood was taken from the mice by right ventricular puncture and
decalcified by adding 1/10 (v/v) 3.2% sodium citrate. For plasma analyses,
decalcified whole blood was centrifuged for 10 min at 2000g and the
resulting plasma supernatant was used. Whole blood was analysed in the
rotational thromboelastometry (ROTEM) delta machine according to
the manufacturer’s instructions using the star-tem, fib-tem, and ex-tem
reagents. Plasma was analysed using the ROTEM mini accessories to
allow for smaller volumes (equipment and reagents by Tem
International GmbH).
2.6 ELISA
Plasma was derived from whole blood as described earlier and was sub-
jected to ELISA for quantifying levels of coagulation factors V, VII, and IX
(all ELISAs from Cloud-Clone Corp.), tissue factor (R&D Systems Inc.)
and tissue factor activity according to manufacturer’s instructions
(Sekisui Diagnostics LLC).
2.7 Whole blood platelet aggregometry
Whole blood was collected as described earlier. Whole blood was
diluted 1:3 in 0.9% saline and aggregometry performed in response to
thrombin (2 U/mL, Sigma–Aldrich) at 37C using impedance aggregome-
try (Chrono-log Corporation).
2.8 Expression analyses
Liver and aortae samples were homogenized using the Precellys 24
homogenizer (Bertin technologies). Total RNA was isolated from
homogenized samples and from isolated human CD14þ cells using TRI
Reagent (Sigma–Aldrich) according to the manufacturer’s instructions
and mRNA was translated to cDNA using Ready-To-Go You-Prime
First-Strand Beads (GE Healthcare). SYBRVR green based real-time quan-
titative PCR (RT-PCR) was carried out according to standard protocol
using a Quant Studio 7 Flex Real Time PCR thermocycler (Applied
Biosystems) and expression calculated using the DDCT method normal-
izing values to expression of GAPDH.
2.9 RT-PCR primers
Primers sequences were obtained from the qPrimer Depot database
(https://mouseprimerdepot.nci.nih.gov/; Wenwu Cui PhD, Laboratory of
Receptor Biology and Gene Expression, National Cancer Institute,
National Institutes of Health). Sequences were synthesized by
Microsynth, Switzerland.
2.10 Statistics
Metric variables were assessed for distribution using the D’Agostino-
Pearson omnibus normality test. For n< 8, non-parametric distribution
was assumed. Different groups were compared using unpaired Student’s
t tests for normally distributed data, or Mann–Whitney tests for data
with non-parametric distribution. P values are two-tailed. Significance
was accepted for P< 0.05. Data are presented as mean ± SD (scatter
plots and table) or as mean± SEM (time-dependent curves). Statistical
analyses were performed using Prism 6 for Mac OS X (GraphPad
Software).
3. Results
3.1 Loss of Sirt3 accelerates time to arterial
thrombotic occlusion in an inflammatory
setting in vivo
To assess the effects of Sirt3 loss-of-function on thrombosis, time to
arterial occlusion was analysed in Sirt3-/- and Sirt3þ/þ WT mice following
laser-induced carotid endothelial injury after lipopolysaccharide (LPS)
challenge (Figure 1A–E). Compared to WT controls, Sirt3-/- mice showed
a 55% reduction in time to occlusion (Figure 1B). A representative blood
flow tracing of one individual animal of each group shows the reduction
of blood flow over the time course of the experiment. The line at
0.1 mL/min indicates the threshold flow regarded as carotid occlusion
(Figure 1C). Initial blood flow and heart rate did not differ between the
two groups (Figure 1D and E).
3.2 Loss of Sirt3 enhances clot formation
and increases clot firmness ex vivo
The effects of Sirt3 deficiency on clotting properties of whole blood
were investigated using ROTEM (Figure 2A). Tomograms analyses from
WT (Figure 2B) and Sirt3-/- whole blood (Figure 2C) revealed that Sirt3-/-
mice displayed an accelerated clotting time (CT, i.e. time to initiation of
clotting) (Figure 2D) and decreased clot formation time (CFT, i.e. time
between initiation of clotting and a clot strength of 20 mm amplitude)
(Figure 2E). Clot firmness was increased over the course of the entire
experiment in whole blood of Sirt3-/- mice compared to WT controls
(Figure 2F). Area under the curve analyses revealed a 30% increase in clot
firmness in Sirt3-/- mice compared to the control group (Figure 2G). The
maximum clot firmness was increased in the Sirt3-deficient group (Figure
2H), whereas time to maximum clot firmness was decreased in Sirt3-/-
compared to WT controls (Figure 2I). These data indicate that Sirt3-/-
mice exhibit altered blood clotting properties independent of the vessel
wall, that cause accelerated thrombotic carotid occlusion in vivo.
3.3 Transcription levels of thrombosis-
associated genes in mouse aortic lysates do
not differ between Sirt3/ andWTmice
To address the involvement of the arterial wall, we assessed transcrip-
tion of key pro- or anticoagulant genes in mouse aortic lysates. These
Sirt3 and arterial thrombosis 3
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..analyses revealed no difference in transcription levels of Ft., Tf pathway
inhibitor (Tfpi), von Willebrand factor (vWf), plasminogen activator inhib-
itor 1 (Pai-1), Pai-2, thrombomodulin (Thbd), intercellular adhesion mole-
cule 1 (Icam-1), vascular cell adhesion molecule 1 (Vcam-1) or tissue
plasminogen activator (tPa), respectively (see Supplementary material
online, Figure S1A–I).
3.4 Cell and platelet depletion in Sirt3/
blood normalize clot formation time and
clot firmness
To differentiate between the contribution of corpuscular vs. soluble
blood components, ROTEM experiments were repeated using platelet-
poor plasma (Figure 3A). The TEMogram of WT plasma (Figure 3B) vs.
Sirt3-/- plasma (Figure 3C) revealed that the clotting time was decreased
in Sirt3-deficient plasma (Figure 3D). Of note, the differences in clot for-
mation time and clot firmness observed in ROTEM experiments using
whole blood were abolished in the absence of blood cells and platelets
(Figure 3E–I), suggesting a role of these blood components in Sirt3-medi-
ated thrombosis.
3.5 Platelets do not play a role in
Sirt3-mediated thrombosis
Platelet counts did not differ between Sirt3-/- and WT mice (see
Supplementary material online, Figure S2A), nor did ex vivo platelet aggre-
gation after stimulation of whole blood with thrombin (see
Supplementary material online, Figure S2B and C). ROTEM analysis
showed that the difference in clotting time was abolished between the
two groups after adding exogenous TF and inhibiting platelet aggregation
(see Supplementary material online, Figure S2D), whereas the other dif-
ferences in clot formation time, clot firmness over time, and maximal
clot firmness persisted (see Supplementary material online, Figure S2E–
H). No difference in time to maximum clot firmness was observed (see
Supplementary material online, Figure S2I).
3.6 Exogenous TF accelerates clotting
initiation in WTwhole blood
ROTEM analysis was performed on whole blood to investigate why the
difference in clotting time was lost after inhibition of platelets and addi-
tion of exogenous TF (as observed in Supplementary material online,
Figure S2D). Addition of exogenous TF without platelet inhibition abol-
ished the difference in clotting time (see Supplementary material online,
Figure S3A). In contrast, the differences in clot formation time, clot firm-
ness over time, and maximal clot firmness persisted between the two
groups (see Supplementary material online, Figure S3B–E). No difference
in time to maximum clot firmness was detected (see Supplementary
material online, Figure S3F).
3.7 Loss of Sirt3 favours NET formation in
mouse neutrophils
After excluding a platelet contribution in Sirt3-mediated thrombosis, we
focused on neutrophils, as they have been shown to be the first cells
Figure 1 Loss of Sirt3 accelerates time to carotid thrombotic occlusion in vivo. Mouse model of laser-induced carotid thrombosis (A): The right carotid
artery was dissected and blood flow measured using a Doppler flow probe (FP). A laser (L) pointing at the carotid artery was exciting a previously intrave-
nously injected photo-reactant resulting in endothelial damage and subsequent thrombus formation. Time to thrombotic occlusion in Sirt3-/- mice was cut in
half compared to WT controls following lipopolysaccharide (LPS) challenge (B). The tracing shows mean blood flow until occlusion (mean flow <_ 0.1 mL for
1 min) (C). Initial blood flow and heart rate remained unaltered between the groups (D and E). n>_ 6, Mann–Whitney test was used for statistical analysis of
all graphs.
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recruited at the site of endothelial damage. Neutrophils were isolated
from BM and stimulated with LPS. NET formation in Sirt3-/- compared to
WT neutrophils was increased early on after stimulation and persisted
for 4 h (Figure 4A). Area under the curve analyses revealed a 75%
increase in NET formation in Sirt3-/- cells over time (Figure 4B).
Representative photomicrographs of unstimulated WT neutrophils, as
well as WT and Sirt3-/- neutrophils after 2 h of LPS stimulation show no
difference in unstimulated vs. stimulated WT cells and a typical net-like
externalization of DNA in the Sirt3-/- group (Figure 4C). Fluorescence-
activated cell sorting (FACS) analysis for the neutrophil markers Ly6G
and CD11b identified 83% of isolated cells as neutrophils (Figure 4D)
and >97% as viable (Figure 4E).
3.8 Loss of Sirt3 increases plasma tissue
factor expression and activity
To address the difference in clotting time between Sirt3-/- and WT con-
trols observed using ROTEM (Figure 2D), and its rescue upon exogenous
TF (see Supplementary material online, Figures S2D and S3A), plasma was
analysed for TF levels and activity. Sirt3-/- mice displayed higher levels of
soluble TF than WT controls (Figure 5A). Increased levels of TF trans-
lated into increased TF activity in the plasma of Sirt3-/- mice compared to
WT controls (Figure 5B). As coagulation factors are predominantly syn-
thesized in the liver, liver lysates were analysed. Expression analyses
revealed elevated mRNA levels of the coagulation factors V, VII, and IX
in Sirt3-/- mice (Figure 5C). However, these results did not translate into
corresponding changes in plasma protein (Figure 5D).
3.9 Frommice to men—reduced Sirt3 and
SOD2 levels in CD14þ leukocytes of
STEMI patients
When comparing BM-derived neutrophils from Sirt3-/- and WT mice by
real-time quantitative PCR, cells lacking Sirt3 (Figure 6A) showed reduced
transcription of Sod2 (Figure 6B). In humans with acute coronary occlu-
sion and STEMI, PCR analyses of CD14þ leukocytes exhibited reduced
transcription levels of both SIRT3 (Figure 6C) and its downstream target
SOD2 (Figure 6D) when compared to the respective cell population of
Figure 2 Loss of Sirt3 accelerates blood clotting and clot firmness ex vivo. Whole blood coagulation was assessed using rotational thromboelastometry
(ROTEM) (A). Once the blood started to coagulate, the rotation of the pin was restricted and the kinetics translated to a TEMogram. Representative pic-
tures show the TEMogram from WT (B) compared to Sirt3-/- whole blood (C). Sirt3-/- blood revealed an earlier onset of clotting (D) and reached a prede-
fined clot firmness earlier than control mice (E). Furthermore, blood of Sirt3-/- animals showed increased clot firmness throughout the experiment (F–H)
and maximum clot firmness was reached earlier (I). n>_ 6, Student’s t-test was used in graph (D) and (I), Mann–Whitney test was applied in graphs (E), (G),
and (H). CT, clotting time (time until initiation of clotting); CFT, clot formation time (time between initiation of clotting and a clot strength of 20 mm
amplitude).
Sirt3 and arterial thrombosis 5
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healthy donors. However, mouse CD11bþ cells lacking Sirt3 (Figure 6D)
showed no difference in Sod2 transcription compared to corresponding
WT cells (Figure 6E). Of note, baseline characteristics of STEMI patients
and healthy donors did not significantly differ for age, gender, BMI, sys-
tolic blood pressure, LDL-cholesterol, and diabetes mellitus—parame-
ters potentially relevant for Sirt3 (Table 1). Increased stress-induced
levels of glucose, C-reactive protein (CRP), and diastolic blood pressure
are to be expected in the acute setting of STEMI as compared to the
quiescent context of healthy donors.
4. Discussion
We here show that genetic loss of Sirt3 in mice accelerates carotid artery
occlusion in vivo under pro-inflammatory conditions. Ex vivo ROTEM
revealed accelerated clot initiation, clot formation, and increased clot
stability in Sirt3-deficient mice. These events were associated with
enhanced formation of thrombogenic NETs, increased expression, and
activity of TF in plasma and reduced Sod2 transcription in neutrophils. In
CD14þ leukocytes isolated from STEMI patients with an acute coronary
occlusion, transcription levels of SIRT3, and its downstream target SOD2
were reduced compared to healthy donors.
In the context of thrombosis, formation of NETs is detrimental
because of their pro-coagulant properties. NETs bind von Willebrand
factor, fibronectin, and fibrinogen, contain inhibitors of the anticoagulant
TFPI, provide a large surface for TF and active coagulation factor XII, and
promote thrombin generation.8,9,24 These properties provide a scaffold
for the binding of platelets and coagulation factors. They also comprise
stimuli for platelet aggregation and activating the coagulation cascade.
Eventually, these events accelerate clot formation and enhance clot
stability, as observed in our ex vivo model.
NET formation can be triggered by ROS and a recent study has dem-
onstrated that mitochondrial ROS are sufficient to generate NETs.4 Sirt3
activates transcription of Sod2, thereby scavenging mitochondrial ROS.
Our findings support the association between mitochondrial ROS and
NET formation by showing that loss of Sirt3 decreases Sod2 transcription
and increases NET formation. The causal role of Sirt3 in protecting
neutrophils from oxidative stress-induced NET formation in animal
Figure 3 Cell depletion of Sirt3-/- blood rescues clot formation time and clot firmness, but not time to initiation of clotting. Murine plasma depleted of all
cells was analysed using ROTEM (A). Once the factors in the plasma started to coagulate, the rotation of the pin was restricted and the kinetics translated to
a TEMogram. Representative pictures show the TEMogram from WT (B) compared to Sirt3-/- plasma (C). Clotting time was reduced in Sirt3-/- vs. WT plasma
(D). No differences could be observed in all other parameters after depleting the blood of cellular components (E–I). n>_ 7, Student’s t-test was used to ana-
lyse graphs (D) and (E) and graphs (G–I) were analysed with the Mann–Whitney test. CT, clotting time (time until initiation of clotting); CFT. clot formation
time (time between initiation of clotting and a clot strength of 20 mm amplitude).
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..models of arterial thrombosis supports earlier findings in healthy humans
where SIRT3 was upregulated after intense exercise, to protect against
neutrophil-mediated oxidative stress.25
The more rapid onset of clotting in our Sirt3-/- ex vivo model using
whole blood could not be reversed after depleting whole blood of its
cellular components and platelets. Yet, we found increased amounts of
active soluble TF in the plasma as a potential mediator. TF and neutro-
phils play indeed a major role in arterial thrombosis as both TF plasma
levels and neutrophil counts are elevated in ACS patients.26 Using a
mouse model of laser-induced thrombosis, another group showed that
TF is expressed by neutrophils and is present in the blood at the site of
injury immediately after laser onset. Upon neutrophil depletion, the
amount of TF in the blood at the site of injury was decreased.3 Likewise,
TF is associated with and expressed in NETs.8,24 These findings suggest
that TF bound to NETs is the reason for increased amounts of active
soluble TF in the plasma.
Taking into account our findings and the detrimental role of NETs in
ischemia-reperfusion injury,27 increased NET formation may explain
recent observations in mice, where Sirt3 deletion impaired left ventricu-
lar recovery after myocardial ischaemia.28
Lastly, we found decreased transcript levels of SIRT3 and SOD2 in
CD14þ cells of STEMI patients with acute coronary occlusion, while we
observed reduced transcription of Sod2 in neutrophils of Sirt3-deficient
mice. Previously, a role for Sirt3 in transcriptional regulation of Sod2 had
only been described in cardiomyocytes via FoxO3.17
4.1 Limitations
Since loss of Sirt3 without an additional stressor does not lead to a phe-
notype, we challenged mice with LPS to mimic a pro-inflammatory state
as it occurs in patients with ACS.29 Even though some triggers of acute
arterial thrombosis may have an infectious source such as acute respira-
tory infections with influenza,30 CVD may develop as a non-infectious
Figure 4 Sirt3 deficiency favours NET formation in bone marrow-derived mouse neutrophils. NET formation over 4 h was evaluated using SYTOX green
nucleic acid stain. Sirt3-/- neutrophils (n=10) showed increased NET formation upon stimulation with 2 lg/mL LPS when compared to WT neutrophils
(n=7) (A). The difference was quantified analysing the area under the curve using the Mann–Whitney test (AUC, B). Representative photomicrographs of
unstimulated WT as well as stimulated WT and Sirt3-/- neutrophils (visualised as white outlines using light microscopy) illustrate NET formation (stained
with SYTOX green) in the Sirt3-deficient group after 2-h stimulation with 2 mg/mL LPS (C, bar=50mm). FACS analyses of cells from a WT mouse showed
that isolated cells were 83% granulocytes (D) and viable (>97%; E). Ly6G, Lymphocyte antigen 6 complex locus G6D; CD11b, cluster of differentiation mole-
cule 11b; CD45.2, cluster of differentiation molecule 45 expressed by Ly5.2 bearing mouse strains; PI, phosphatidylinositol.
Sirt3 and arterial thrombosis 7
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..chronic inflammatory disease.31 Moreover, recent studies suggest that
the gut microbiome enhances CVD and neutrophil pro-inflammatory
activity6,32 and impairs outcome in patients with ACS.33
Due to a lack of availability of human neutrophil samples, we used
human CD14þ leukocytes. With both neutrophils and monocytes being
leukocyte subsets, we postulated that a differential expression of SIRT3
in human monocytes may parallel a differential expression in murine neu-
trophils. Furthermore, we isolated mouse CD11bþ cells, the mouse
equivalent to human CD14þ cells. Since we could not replicate the
changes seen in human CD14þ in murine CD11bþ cells, our data sug-
gest that an extrapolation between mouse and human leukocytes has to
be done with caution. Our findings also suggest that SOD2 in human neu-
trophils may not fully account for SIRT3-mediated NET formation. A
possible reason for the changes in monocytic SIRT3 expression in
humans may lie in the fact that STEMI patients usually suffer from inflam-
mation and atherosclerosis for years before myocardial infarction. Thus,
downregulation of SIRT3 in this case may be a reaction to this chronic
condition, which was not replicated in mice apart from exposing them
acutely with LPS.
Along the same line, our mouse expertiments highlight a proof-of-
principle and causality between Sirt3 deficiency and the thrombosis phe-
notype in a non-atherosclerotic carotid artery. In humans, context and
protagonist cells are different—and we describe an association between
decreased SIRT3 in monocytes of STEMI patients. We did not address
NETosis and SIRT3 in humans, yet increased tissue factor and NETosis
have been reported in culprit coronary arteries of patients with acute
myocardial infarction.8 Nevertheless, a Sirt3-mediated effect on murine
NET formation does exist and our data do not exclude an effect of Sirt3-
deficiency on human neutrophils. To test the translatability, our findings
have to be replicated in neutrophils from human STEMI patients.
Even though increased TF in plasma may be mainly derived from acti-
vated neutrophils, monocytes may contribute, as they have been
described to release TF microvesicles.34 It is conceivable that the initial
release of TF originates from neutrophils, as they are the first cells to
reach the site of injury.3 Subsequent release of TF from monocytes is
likely to be triggered by interactions between neutrophils and the endo-
thelium. Notably, since the discovery of NETs, other types of leukocytes
were also shown to release extracellular mitochondrial DNA traps.35,36
It is possible that these leukocytes contribute to the effects observed
in vivo and ex vivo.
4.2 Conclusions and perspectives
Our study highlights a protective role of Sirt3 in neutrophils in a mouse
model of acute carotid thrombosis under inflammatory conditions. In
line with these findings, acute coronary thrombosis in STEMI patients is
associated with decreased protective factors such as lower SIRT3 and
SOD2 levels in CD14þ cells. Future studies in neutrophils of patients
with myocardial infarction should be done to more specifically address
the association between neutrophil-derived SIRT3, SOD2 levels, and
NET formation.
Based on our results, we postulate that activation of SIRT3 in ACS
may improve outcome of STEMI patients by reducing NET-dependent
procoagulatory properties. As NETs are described in a variety of other
non-infectious diseases,37 SIRT3 activation may also provide beneficial
Figure 5 Loss of Sirt3 increases plasma TF levels and activity. Sirt3-/- animals showed increased TF levels (A, n>_ 6, Mann–Whitney test) and a higher TF activity
(B, n>_ 9, Student’s t-test) in plasma than in control animals. Liver mRNAs of locally synthesized coagulation factors V, VII, and IX were elevated in Sirt3-/- animals
(C, n= 9, *: P= 0.0385 and 0.0402; **: P= 0.0078, factor VII and XI were analysed using the Mann–Whitney test, the other factors with Student’s t-test).
However, protein plasma levels were not different (D, n= 8, Factor V analysed by Mann–Whitney test, factors VII and IX by Student’s t-test).
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effects in these disease contexts. Indeed, the therapeutic potential of
specific sirtuin activators in CVD has been reported.18 However, to date
no clinically effective specific activator of any of the seven sirtuins has
been identified. Investing in the discovery of new substances that can
specifically activate certain sirtuins could open new therapeutic possibil-
ities for CVD, as well as other metabolic and age-related diseases.
Promising alternative approaches could be to boost SIRT3 expression
by transcriptional activation or to use CRISPR technology. Finally, since
beneficial roles in CVD have been described also for other sirtuins,18
pan-sirtuin activators appear worthy for clinical testing. Recently, the first
pilot study using the NADþ precursor nicotinamide riboside (NR) has
been completed38 and on-going clinical studies are investigating the
effect of NR on aging, obesity, insulin resistance, and coronary artery
disease.
Figure 6 Sod2 transcription is reduced in Sirt3-deficient mouse neutrophils, but not in monocytes—CD14þ leukocytes of STEMI patients show reduced
SIRT3 and SOD2 transcript levels. Murine Sirt3-/- neutrophils lack Sirt3 (A) and show reduced transcription of Sod2 (B, n>_ 8, Student’s t-test). STEMI patients
demonstrate reduced mRNA levels of SIRT3 (C) and SOD2 (D) in CD14þ cells compared to healthy donors (n= 10, both Student’s t-test). CD11bþ cells
from Sirt3-deficient mice show no differential transcription of Sod2 compared to WT (E and F, n= 6, Mann–Whitney test).
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Supplementary material
Supplementary material is available at Cardiovascular Research online.
Acknowledgements
We thank the catheter team and study nurse Anika Adam at the
University Heart Center in Zurich for recruiting patients and healthy
donors, and Aliki Buhayer (PRISM Scientific Sa`rl) for her support in med-
ical writing. Figure 7 was designed using Servier Medical Art by Servier
under a Creative Commons Attribution 3.0 Unported License.
Conflict of interest: C.M.M. received research grants from Swiss
National Science Foundation, from the University Research Priority
Program Integrative Human Physiology at the University of Zurich, and
from Hartmann-Mu¨ller Foundation during the conduct of the study, as
well as grants from MSD, Bayer, AstraZeneca, EliLilly, and speaker fees
from MSD, AstraZeneca, Roche, Sanofi, and Amgen outside the submit-
ted work. T.F.L. received grants to the institution from Amgen,
AstraZeneca, Bayer Healthcare, Biosensors, Biotronik, Boston Scientific,
Eli Lilly, Medtronic, MSD, Merck, Roche and Servier, including speaker
fees by some of them. S.W. received grants from Biotronik, Bacco
Pharmaceutical, Edwards Lifesciences, Medtronic, and Terumo Inc, as
well as grants and speaker fees from Boston Scientific and Daiichi
Sankyo, all outside the submitted work. J.A. is a founder and scientific
advisory board member of Mitobridge.
Funding
This work was supported by the Swiss National Science Foundation
[31003 A-140780 to J.A., 310030-135815 to T.F.L., 310030-146923 to
Figure 7 Scheme illustrating prothrombotic effects of Sirt3 deficiency. Upon pro-inflammatory stimuli such as bacterial endotoxins (e.g. LPS) or oxLDL
known to trigger human atherothrombotic events, endogenous Sirt3 protects neutrophils from NET formation (left). In contrast, absence of Sirt3 favours
NETs, thereby accelerating clotting and increasing clot firmness (right) in mice. In patients with STEMI, SIRT3 transcription levels are reduced.
......................................................................................................
Table 1 Baseline characteristics of healthy donors and
STEMI patients
Healthy STEMI P value
n 10 10
Gender (f/m) 4/6 2/8 0.63a
Age (years) 58±8 62±9 0.39b
BMI (kg/m2) 24.0±3.1 26.1±3.3 0.13b
Time to catheterization (h) – 6.76±9.3 –
Systolic blood pressure (mmHg) 119.1±9.0 123.2±29.3 0.84a
Diastolic blood pressure (mmHg) 71.0±8.8 82.3±16.3 0.046a
Diabetes history (f/m) 0/0 0/0 –
Fasting glucose (mmol/L) 5.1±0.6 7.3±1.2 <0.0001a
Total cholesterol (mmol/L) 5.3±0.8 5.5±1.6 0.75b
HDL (mmol/L) 1.7±0.5 1.3±0.3 0.017b
LDL (mmol/L) 3.2±0.6 3.5±1.3 0.47b
Triglycerides (mmol/L) 1.0±0.4 0.9±0.4 0.57b
CRP (mg/L) 1.3±1.5 11.3±10.5 0.064a
Creatinine (mmol/L) 87.3±10.7 83.3±14.3 0.49b
Statins (f/m) 0/0 1/3 –
Aspirin (f/m) 0/0 1/2 –
m/f, number of males/females; BMI, body mass index; time to catheterization, time
between pain onset and sheath insertion in the catheterization laboratory; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein. n= 10.
aMann–Whitney test.
bStudent’s t-test.
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